ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

16 Tips from 16 Years Sick

Fibromyalgia Fare Fit for All Seasons

New Study Shows Artificial Sweeteners Lead to Diabetes

Essential Oils — An Effective and Healthy Option to Treat Headaches

Antioxidant treatment could halt neurodegeneration in early Parkinson's

Higher vitamin D levels associated with less severe disease in NAFLD patients

Krill Oil: Make This Omega-3 Supplement Part of Your Health Regimen

How zinc helps fight esophageal cancer

Everything You Need to Know About Black Cohosh

Low vitamin D levels predict ED in diabetics

 
Print Page
Email Article

Novel Oral Drug for Rheumatoid Arthritis Completes Phase I Clinical Trial

  [ 9 votes ]   [ Discuss This Article ]
www.ProHealth.com • October 26, 2001




AGIX -4207, a novel oral agent being developed for the treatment of rheumatoid arthritis, has completed the escalating single-dose segment of its Phase I clinical trial. This is according to a recent announcement by the drugs manufacturer, AtheroGenics, Inc.

AGIX-4207 is a small molecule drug that represents a unique approach to treating rheumatoid arthritis. Unlike currently marketed biological TNF-alpha (tumor necrosis factor-alpha) inhibitors, AGIX-4207 is a selective modulator of TNF-alpha induced redox-sensitive inflammatory genes. By targeting a specific subset of TNF-alpha activity, it is believed that AGIX-4207 may decrease chronic inflammation in rheumatoid arthritis, while maintaining the body's ability to respond to infection.

The Phase I clinical trial is designed to study the safety, tolerability and pharmacokinetics of single and multiple doses of AGIX-4207 in healthy volunteers. A total of 48 patients in the single-dose segment of the Phase I trial received oral doses of AGIX-4207, ranging from 1mg to 150mg. AGIX-4207 was well tolerated by all patients, and there were no serious adverse events occurring in patients who received the drug. The data have been submitted to the U.S. Food and Drug Administration for review, and a multi-dose segment of the study is expected to be completed by the end of the year.

"We are delighted that AGIX-4207 has successfully completed this first stage of the trial, and we look forward to completing the multi-dosing before the end of this year," said AtheroGenics President and Chief Executive Officer, Russell Medford, M.D., Ph.D. "As we progress through these clinical trial milestones, we remain hopeful that AGIX-4207 might eventually provide those who suffer from rheumatoid arthritis with a safe and effective treatment option for their health and well being."

Rheumatoid arthritis is a chronic and progressively debilitating inflammatory disease that affects more than two million patients in the United States. Approximately 70 percent of those diagnosed with rheumatoid arthritis are young and middle-aged women. Physicians currently treat chronic rheumatoid arthritis in a stepwise fashion, escalating from a regimen of common anti-inflammatory agents like aspirin or ibuprofen, to the use of increasingly toxic drugs that may affect the body's immune system, such as DMARDs (Disease Modifying Anti-Rheumatic Drugs) or biological TNF-alpha inhibitors.



Post a Comment

Featured Products From the ProHealth Store
Optimized Curcumin Longvida® Vitamin D3 Extreme™ Ultra ATP+, Double Strength


Article Comments



Be the first to comment on this article!

Post a Comment


 
Optimized Curcumin Longvida with Omega-3

Featured Products

Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils

Natural Remedies

Pioneer Scientists Uncover a Revolutionary Neuroprotective Supplement for Nerve Health Pioneer Scientists Uncover a Revolutionary Neuroprotective Supplement for Nerve Health
Undenatured Type II Collagen - Chicken Soup for Your Joints Undenatured Type II Collagen - Chicken Soup for Your Joints
Breakthrough Form of Magnesium Enhances Memory and Cognitive Function Breakthrough Form of Magnesium Enhances Memory and Cognitive Function
Complete and Natural Menopause Relief Complete and Natural Menopause Relief
Curcumin - a Golden Gift of Nature with Benefits Still Untold Curcumin - a Golden Gift of Nature with Benefits Still Untold

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map